Stock AnalizTrevi Therapeutics, Inc. TRVI
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Trevi Therapeutics, Inc. (TRVI) is a healthcare company listed in the US with a market value of about $1.9B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -67%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$43M | -$48M | -$29M | -$29M | -$34M | -$33M | -$26M | -$21M |
| Free cash flow | -$42M | -$38M | -$32M | -$28M | — | -$29M | -$23M | -$18M |
| EPS (diluted) | $-0.32 | $-0.47 | $-0.29 | $-0.45 | $-1.49 | $-1.81 | $-2.28 | $-58.44 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -26.8% | -51.2% | -40.5% | -27.8% | -188.5% | -117.9% | -48.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $28.18, 106% above the current price; targets range from $23.00 to $40.00; the consensus rating is “Strong buy”; expected EPS is $-0.50 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Trevi Therapeutics pay a dividend?
Not currently.
Is Trevi Therapeutics a good stock to buy?
We do not give buy or sell advice. Trevi Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.